Venus MedTech Appoints Shakeel Osman as Senior Vice President of Sales for Europe to Drive Commercialization of VenusP-Valve

Hangzhou, March 18, 2022 /PRNewswire/ -- On March 18, 2022, Venus Medtech (Hangzhou) Inc., a leading provider of comprehensive solutions for structural heart disease in China,（“Venus Medtech”，2500.HK) announced the appointment of Shakeel Osman as Senior Vice President of European Sales, responsible for the commercialization and promotion of the congenital heart disease business. Currently, Venus Medtech's pulmonary valve replacement system, VenusP-Valve, designed for patients with congenital heart disease, is in the approval pending stage.

JoinVenus MedtechPreviously, Shakeel Osman worked at Occlutech, a well-known supplier of structural heart disease devices, serving as the Vice President of Sales for the Middle East, Africa, East Asia, and Ireland, as well as the General Manager of Occlutech UK. With 20 years of experience in international medical device marketing, Shakeel Osman has deep expertise in the European and Middle Eastern markets and extensive experience in marketing, promotion, and distributor management within the cardiovascular field.

Shakeel Osman stated:“I am very honored to join the European commercialization team of Venus Medtech. As a leader in structural heart disease, Venus Medtech’s innovative pipeline boasts strong international competitiveness. I will leverage my extensive marketing experience and collaborate closely with everyone to lay a solid foundation for the full commercial promotion of VenusP-Valve in Europe, driving the implementation of the company's international strategy.”

VenusP-Valve is currently the only self-expanding pulmonary valve replacement system under review in Europe, and it is the second innovative medical device from Venus Medtech, after the distal cerebral embolic protection system TriGUARD3™, with the potential for commercialization in the European market. The product received a special use authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in March 2021.

Venus MedtechFounder, Executive Director and General Manager Zhenjun Zi extended a warm welcome to Shakeel Osman's joining.“We are delighted to welcome another professional and seasoned expert in medical device marketing to Venus Medtech. With Shakeel Osman's extensive experience in market promotion, the commercial rollout of VenusP-Valve in Europe will be significantly strengthened. This will also bring substantial value to the company’s future clinical development of innovative devices in Europe.”

Following the European launch of TriGUARD3™ in 2020, Venus Medtech has been committed to continuously enhancing its international commercialization capabilities, laying a solid foundation for global innovation, with the aim of introducing more structural heart disease products into international clinical use. This time,Venus MedtechMeanwhile, David Breant has been appointed as the Vice President of Sales for Europe, overseeing the adult structural heart disease business and direct sales operations in regions such as Germany and France; Joyce Heo has been appointed as Sales Director, responsible for sales operations in emerging markets.